A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Clinical trial NCT02202746 · TERMINATED

Trial details

NCT number: NCT02202746
Sponsor: Clovis Oncology, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Metastatic Breast Cancer MBC HER2 Positive HER2 Estrogen Receptor Positive ER Triple Negative

Start date: 2014-09-09
Primary completion: 2017-01-17
Enrollment: 178

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.